UNITED LAB Receives $13.5 Million Milestone Payment from Novo Nordisk for UBT251 Exclusive License

Stock News07-16 12:07

UNITED LAB (HKEX: 03933) has announced that its subsidiary, United Biotech, received a milestone payment of $13.5 million from Novo Nordisk on July 15, 2026. This payment, net of Danish withholding tax, was triggered by the global Phase I clinical milestone for the overweight or obesity indication of the UBT251 injection.

The terms of the exclusive licensing agreement stipulate that United Biotech is eligible to receive up to a total of $1.8 billion in potential milestone payments. These payments are contingent upon achieving specific development and sales milestones. Furthermore, the company is entitled to receive tiered royalties based on the annual net sales of the product in the licensed region.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160718309?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 12:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160718309","market":"us","top_or_hot":-1,"title":"UNITED LAB Receives $13.5 Million Milestone Payment from Novo Nordisk for UBT251 Exclusive License","media":"Stock News","content":"<p><b>UNITED LAB</b> (<b>HKEX: 03933</b>) has announced that its subsidiary, United Biotech, received a milestone payment of $13.5 million from Novo Nordisk on July 15, 2026. This payment, net of Danish withholding tax, was triggered by the global Phase I clinical milestone for the overweight or obesity indication of the UBT251 injection.<br><br>\nThe terms of the exclusive licensing agreement stipulate that United Biotech is eligible to receive up to a total of $1.8 billion in potential milestone payments. These payments are contingent upon achieving specific development and sales milestones. Furthermore, the company is entitled to receive tiered royalties based on the annual net sales of the product in the licensed region.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UNITED LAB Receives $13.5 Million Milestone Payment from Novo Nordisk for UBT251 Exclusive License</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUNITED LAB Receives $13.5 Million Milestone Payment from Novo Nordisk for UBT251 Exclusive License\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-16 12:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>UNITED LAB</b> (<b>HKEX: 03933</b>) has announced that its subsidiary, United Biotech, received a milestone payment of $13.5 million from Novo Nordisk on July 15, 2026. This payment, net of Danish withholding tax, was triggered by the global Phase I clinical milestone for the overweight or obesity indication of the UBT251 injection.<br><br>\nThe terms of the exclusive licensing agreement stipulate that United Biotech is eligible to receive up to a total of $1.8 billion in potential milestone payments. These payments are contingent upon achieving specific development and sales milestones. Furthermore, the company is entitled to receive tiered royalties based on the annual net sales of the product in the licensed region.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03933","symbol_name":"联邦制药","start_time":0,"source_url":"","article_id":"1160718309","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160718309","pubTimestamp":1784174837,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"UNITED LAB (HKEX: 03933) has announced that its subsidiary, United Biotech, received a milestone payment of $13.5 million from Novo Nordisk on July 15, 2026. This payment, net of Danish withholding...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03933":"联邦制药","BK1191":"制药","IE00B3M56506.USD":"NEUBERGER BERMAN EMERGING MARKETS EQUITY \"A\" (USD) ACC"},"translate_title":"UNITED LAB 收到诺和诺德 1350 万美元的 UBT251 独家许可证里程碑付款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":1},"content_text":"UNITED LAB (HKEX: 03933) has announced that its subsidiary, United Biotech, received a milestone payment of $13.5 million from Novo Nordisk on July 15, 2026. This payment, net of Danish withholding tax, was triggered by the global Phase I clinical milestone for the overweight or obesity indication of the UBT251 injection.\nThe terms of the exclusive licensing agreement stipulate that United Biotech is eligible to receive up to a total of $1.8 billion in potential milestone payments. These payments are contingent upon achieving specific development and sales milestones. Furthermore, the company is entitled to receive tiered royalties based on the annual net sales of the product in the licensed region.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160718309","isCrawlerRequest":true}